Second malignant tumors in childhood cancer survivors

Abstract

The growing incidence of individuals surviving childhood cancer has increased the awareness of adverse long term sequelae One of the most unpleasant complications after cancer therapy is development of second malignant neoplasms The risk of second malignancies is 2 3 times higher childhood cancer survivors and 20 year cumulative risk of secondary malignancies was reported as 3 2 In this paper the risk factors differences according to cancer and therapy type and management strategies for secondary neoplasms in childhood cancer survivors were reviewed Turk Arch Ped 2011; 46: 270 4

Keywords

• -

Çocukluk çağı kanser sağ kalanlarında ikincil kanserler

Abstract

Çocukluk çağı kanserleri sağkalım oranlarının artması ile dikkatler tedaviye bağlı geç yan etkiler üzerinde yoğunlaşmaya başlamıştır Kanser tedavisinin en önemli komplikasyonlarından biri de ikincil kanserlerdir Çocukluk çağında kanser geçiren olgularda ikincil malinitelerin riski 2 3 kat daha fazladır ve 20 yılda 3 2 olarak bildirilmiştir Bu yazıda kanserden kurtulmuş çocuk hastalarda ikincil kanser oluşumundaki risk etmenleri kanser tipine ve tedavi şekline göre farklılıkları ile hastaların takibindeki özellikler irdelenmiştir.

Keywords

• Çocuk kanserleri
• geç yan etki
• ikincil kanserler

References

1. Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA 2007; 297: 2762-4.
2. Varan A, Kebudi R. Secondary malignant neoplasms after childhood cancer. Pediatr Hematol Oncol 2011; 28: 345-53.
3. MacArthur AC, Spinelli JJ, Rogers PC, Goddard KJ, Phillips N, McBride ML. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada. Pediatr Blood Cancer 2007; 48: 453-9.
4. Lawless SCW, Verma P, Green DM, Mahoney MC. Mortality experiences among 15+ year survivors of childhood and adolescent cancers. Pediatr Blood Cancer 2007; 48: 333-8.
5. Olsen JH, Moller T, Anderson H, et al. Lifelong cancer incidence in 47 697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009; 101: 806-13.
6. Robison LL, Gren DM, Hudson M, et al. Long term outcomes of adult survivors of childhood cancer. Cancer 2005; 104(Suppl): 2557-64.
7. Orkin SH, Fisher DE, Look AT, Lux SE, Ginsburg D, Nathan DG. Oncology of infancy and childhood. 1st ed. Philadelphia: Elsevier, 2009: 1255-89.
8. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009; 27: 2356-62.

9. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer 2007; 43: 351-62.
10. Çağlar K, Varan A, Akyüz C, et al. Second neoplasms in pediatric patients treated for cancer: a center’s 30- year experience. J Pediatr Hematol Oncol 2006; 28: 374-8.
11. Kebudi R, Ayan İ, Görgün Ö, et al. Second malignant tumors in childhood cancer survivors. Pediatr Blood Cancer 2007; 49: 553.
12. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-8.
13. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997; 15: 177-202.
14. Mocellin S, Verdi D, Nitti D. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta-analysis. Carcinogenesis 2009; 30: 1735-43.
15. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risk after radiotherapy. J Clin Oncol 2006; 24: 2570-5.
16. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de nova acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091-5.
17. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment related lukemia. Proc Natl Acad Sci USA 1998; 95: 13176-81.
18. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25: 27-65.
19. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 1995; 87: 1530-7.
20. Rothman K, Keller A. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. J Chronic Dis 1972; 25: 711-6.
21. Demirci U, Buğdayci F, Cakir A, et al. Bilateral breast cancer in a survivor of acute lymphoblastic leukemia: a case report. Med Oncol 2010; 27: 481-3.
22. Pui CH, Riberio RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-7.
23. Bhatia S, Kralio MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: a report from the children’s Oncology Group. Blood 2007; 109: 46-51.
24. Ng AK, Mauch PM. The impact of treatment on the risk of second malignancy after Hodgkin’s disease. Ann Oncol 2006; 17: 1727-9.
25. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386-94.
26. Metayer C, Lynch C, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-43.
27. Diller L, Medeiros Nancarrow C, Shaffer K, et al. Breast cancer screening in women previously treated for Hodgkin’s disease: a prospective cohort study. J Clin Oncol 2002; 20: 2085-91.
28. Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of breast cancer after Hodgkin’s disease. J Clin Oncol 2000; 18: 765-72.
29. Travis L, Gospodarowicz M, Curtis R, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002; 94: 182-91.
30. Williams D. Radiation carcinogenesis: lessons from Chernobyl. Oncogene 2008; 27 (Suppl2): 9-18.
31. Gurney JG, Davis S, Severson RK, Robison LL. The influence of subsequent neoplasms on incidence trends in childhood cancer. Cancer Epidemiol Biomarkers Prev 1994; 3: 349-51.
32. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325: 1330-6.
33. Tucker MA, Jones PH, Boice JDJ, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991; 51: 2885-8.
34. de Vathaire F, Hardiman C, Shamsaldin A, et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 1999; 159: 2713-9.
35. Tucker MA, D’Angio GL, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588-93.
36. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996; 88: 270-8.
37. Le Vu B, de Vathaire F, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998; 77: 370-7.
38. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up childhood Hodgkin’s disease: Report from the Late Effects Study Group. J Clin Oncol 2003; 21: 4386-94.
39. Bacci G, Longhi A, Barbieri E, et al. Second malignancy in 597 patients with Ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. J Pediatr Hematol Oncol 2005; 27: 517-20.
40. Ergun - Longmire B, Mertens AC, Nitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91: 3494-8.
41. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomized trials. Ann Oncol 2006; 17: 1749-60.